NCT01702337View on ClinicalTrials.gov

Prevalence-based Health and Economic Model of the Bivalent Versus the Quadrivalent Human Papillomavirus (HPV) Vaccine

CompletedOBSERVATIONAL
Enrollment

1

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Human Papillomavirus Infection
Interventions
OTHER

Prevalence-based model

Static prevalence-based model to estimate vaccine effect over a one-year period at a steady state (when all women are fully vaccinated).

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01702337 - Prevalence-based Health and Economic Model of the Bivalent Versus the Quadrivalent Human Papillomavirus (HPV) Vaccine | Biotech Hunter | Biotech Hunter